SANUWAVE HEALTH COMPLETES ACQUISITION OF

SANUWAVE HEALTH COMPLETES ACQUISITION OF

THE WOUND CARE ASSETS OF CELULARITY

CONFERENCE CALL SCHEDULED FOR WEDNESDAY 1 P.M. EDT

SUWANEE, GA, August 10, 2020 - SANUWAVE Health,

Inc. (OTCQB: SNWV) today announced that it has completed the

acquisition of the wound care assets of Celularity, consisting of

the UltraMIST Ultrasound Healing Therapy assets and

partnership rights for Celularity's wound care biologic

The funding for the acquisition consisted of a mix of funded term

debt, a seller note, and equity in the form of a private placement.

The private placement generated gross proceeds of approximately $24

million through the issuance of 119,125,000 shares of common stock

and accompanying warrants to purchase up to an equal number of

shares of common stock at a purchase price of $0.20 per share of

common stock and accompanying warrants. The warrants will be exercisable immediately at an

exercise price of $0.25 per share and will expire three years after

the date of issuance. Over

60% of the private placement was purchased by existing investors

and insiders, and the remainder was purchased by certain healthcare

focused institutional and accredited investors.

H.C Wainwright & Co. acted as the exclusive placement agent for

the private placement. Lake Street Capital Markets acted as

financial advisor for the acquisition and the private

William Blair & Company acted as the sole placement agent of

The acquisition is expected to be a transformative event for

SANUWAVE and represents a strategically and financially compelling

growth opportunity for the company. The transaction broadens

SANUWAVE's addressable market and combines two highly

complementary energy transfer technologies with two biologic skin

substitute products to create a platform of scale with an

end-to-end product offering in the advanced wound care market.

Furthermore, it uniquely positions SANUWAVE to address the entire

advanced wound care patient pathway from the initial stages of

treatment to closure. The treatment combination of the

UltraMIST and the dermaPACE System creates a

significant opportunity to demonstrate improved patient outcomes

over the current standard of care, initially for diabetic foot

ulcers and across all wound indications in the future.

will conduct an investor teleconference at 1:00 p.m. EDT on

Wednesday, August 12, 2020. A separate press release will be issued

providing the conference call information. More details regarding

the acquisition and the future plans will be shared and detailed on

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com)

is a shockwave technology company initially focused on the

development and commercialization of patented noninvasive,

biological response activating devices for the repair and

regeneration of skin, musculoskeletal tissue and vascular

structures. SANUWAVE's portfolio of regenerative medicine

products and product candidates activate biologic signaling and

angiogenic responses, producing new vascularization and

microcirculatory improvement, which helps restore the body's

normal healing processes and regeneration. SANUWAVE applies its

technology in wound healing,

orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead

product candidate for the global wound care market,

is US FDA cleared for the treatment of Diabetic Foot Ulcers.

The device is also CE Marked throughout Europe and has device

license approval for the treatment of the skin and subcutaneous

soft tissue in Canada, South Korea, Australia and New Zealand.

SANUWAVE researches, designs, manufactures, markets and services

its products worldwide, and believes it has demonstrated that its

technology is safe and effective in stimulating healing in chronic

conditions of the foot (plantar fasciitis) and the elbow (lateral

epicondylitis) through its U.S. Class III PMA approved

as well as stimulating bone and chronic tendonitis regeneration in

the musculoskeletal environment through the utilization of its

OssaTron, Evotron and

in Europe, Asia and Asia/Pacific. In addition, there are

license/partnership opportunities for SANUWAVE's shockwave

technology for non-medical uses, including energy, water, food and

About Celularity Inc.

Celularity, headquartered in Warren, N.J., is a clinical-stage cell

therapeutics company delivering transformative allogeneic cellular

therapies derived from the postpartum human placenta. Using

proprietary technology in combination with its IMPACT

platform, Celularity is the only company harnessing the purity and

versatility of placental-derived cells to develop and manufacture

innovative and highly scalable off-the-shelf treatments for

patients with cancer, inflammatory, infectious, and age-related

diseases. To learn more, please visit www.celularity.com.

Forward-Looking Statements

This press release may contain forward-looking

statements within the meaning of the Private Securities

Litigation Reform Act of 1995, such as statements relating to

financial results and plans for future business development

activities and are thus prospective. Forward-looking statements

include all statements that are not statements of historical fact

regarding intent, belief or current expectations of SANUWAVE

Health, Inc. (the Company ), its directors or its

officers, including, without limitation, any statements regarding

any expected benefits of the acquisition and its impact on the

Company. Investors are cautioned that any such forward-looking

statements are not guarantees of future performance and involve

risks and uncertainties, many of which are beyond the

Company's ability to control. Actual results may differ

materially from those projected in the forward-looking statements.

Among the key risks, assumptions and factors that may affect

operating results, performance and financial condition are risks

associated with the regulatory approval and marketing of the